BRCA Testing Dichotomy in Saudi Arabia.
作者信息
Abusanad Atlal
机构信息
King Abdulaziz University, Jeddah, Saudi Arabia.
出版信息
J Glob Oncol. 2019 Jan;5:1-2. doi: 10.1200/JGO.18.00188.
Abstract
摘要
相似文献
1
BRCA Testing Dichotomy in Saudi Arabia.沙特阿拉伯的BRCA检测二分法
J Glob Oncol. 2019 Jan;5:1-2. doi: 10.1200/JGO.18.00188.
2
Genetic Testing After Previous BRCA Testing: A Case Study.先前BRCA检测后的基因检测：一个案例研究。
Clin J Oncol Nurs. 2016 Dec 1;20(6):660-663. doi: 10.1188/16.CJON.660-663.
3
Genetic/familial high-risk assessment: breast and ovarian.遗传/家族性高风险评估：乳腺癌和卵巢癌。
J Natl Compr Canc Netw. 2010 May;8(5):562-94. doi: 10.6004/jnccn.2010.0043.
4
BRCA screening.BRCA基因检测
Med Lett Drugs Ther. 2007 Nov 19;49(1274):93-4.
5
The case against BRCA 1 and 2 testing.反对BRCA 1和2基因检测的理由。
Surgery. 2011 Jun;149(6):731-4. doi: 10.1016/j.surg.2010.11.009.
6
Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.生殖系BRCA检测正从癌症风险评估转向一种用于靶向癌症治疗的预测性生物标志物。
Clin Transl Oncol. 2016 Oct;18(10):981-7. doi: 10.1007/s12094-015-1470-0. Epub 2016 Jan 7.
7
BRCA to the future: towards best testing practice in the era of personalised healthcare.BRCA走向未来：迈向个性化医疗时代的最佳检测实践。
Eur J Hum Genet. 2016 Sep;24 Suppl 1(Suppl 1):S1-2. doi: 10.1038/ejhg.2016.92.
8
Increased Reach of Genetic Cancer Risk Assessment as a Tool for Precision Management of Hereditary Breast Cancer.扩大遗传性乳腺癌精准管理工具——遗传癌症风险评估的应用范围
JAMA Oncol. 2016 Jun 1;2(6):723-4. doi: 10.1001/jamaoncol.2015.5975.
9
Finding all BRCA pathogenic mutation carriers: best practice models.寻找所有BRCA致病突变携带者：最佳实践模式。
Eur J Hum Genet. 2016 Sep;24 Suppl 1(Suppl 1):S19-26. doi: 10.1038/ejhg.2016.95.
10
Breast-cancer risk in BRCA-mutation-negative women from BRCA-mutation-positive families.BRCA基因突变阳性家族中BRCA基因突变阴性女性的乳腺癌风险。
Lancet Oncol. 2007 Dec;8(12):1042-1043. doi: 10.1016/S1470-2045(07)70348-0.
本文引用的文献
1
Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer.沙特高危乳腺癌患者中BRCA1和BRCA2基因突变的患病率
J Glob Oncol. 2018 Aug;4:1-9. doi: 10.1200/JGO.18.00066.
2
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.他拉唑帕尼治疗携带有胚系 BRCA 突变的晚期乳腺癌患者。
N Engl J Med. 2018 Aug 23;379(8):753-763. doi: 10.1056/NEJMoa1802905. Epub 2018 Aug 15.
3
Clinical Cancer Genetics in a Lower-Middle Income Country: Considerations for Policymaking.低收入和中等收入国家的临床癌症遗传学：政策制定考量
J Glob Oncol. 2018 Jul;4:1-3. doi: 10.1200/JGO.18.00081.
4
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.聚腺苷二磷酸核糖聚合酶抑制剂在 BRCA1/2 突变相关和 BRCA 样恶性肿瘤中的应用。
Ann Oncol. 2014 Jan;25(1):32-40. doi: 10.1093/annonc/mdt384. Epub 2013 Nov 12.
5
Social and ethical implications of BRCA testing.BRCA 检测的社会伦理影响。
Ann Oncol. 2011 Jan;22 Suppl 1:i60-6. doi: 10.1093/annonc/mdq668.
6
PARP inhibition in BRCA-mutated breast and ovarian cancers.BRCA 突变的乳腺癌和卵巢癌中的 PARP 抑制作用。
Lancet. 2010 Jul 24;376(9737):211-3. doi: 10.1016/S0140-6736(10)61119-1.
7
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.奥拉帕利在携带 BRCA1 或 BRCA2 突变的复发性卵巢癌患者中的疗效：一项概念验证试验。
Lancet. 2010 Jul 24;376(9737):245-51. doi: 10.1016/S0140-6736(10)60893-8. Epub 2010 Jul 6.
8
Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer.非小细胞肺癌中表皮生长因子受体体细胞突变和基因拷贝数增加作为酪氨酸激酶抑制剂反应的预测生物标志物。
Clin Cancer Res. 2010 Jan 1;16(1):291-303. doi: 10.1158/1078-0432.CCR-09-1660. Epub 2009 Dec 22.
9
Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma.表皮生长因子受体（EGFR）酪氨酸激酶结构域中的体细胞突变可消除非小细胞肺癌中EGFR介导的辐射防护作用。
Cancer Res. 2007 Jun 1;67(11):5267-74. doi: 10.1158/0008-5472.CAN-07-0242.
10
Moving genetics into clinical cancer care: examples from BRCA gene testing and telemedicine.
Breast. 2006 Dec;15 Suppl 2:S65-70. doi: 10.1016/S0960-9776(07)70021-8.
Zotero 插件